FDAnews Drug Daily Bulletin

Pharma Blog Watch

Feb. 15, 2013
A A
Merck Pays $688M to Settle Suits Over Enhance Trial (Pharmalot Blog)
Merck has agreed to settle shareholder lawsuits over the highly controversial Enhance clinical trial for the Vytorin (Ezetimibe/simvastatin ) cholesterol pill, resolving two separate lawsuits in which the drugmaker has agreed to make a total payment of $688 million, described as one of the 25 largest securities class action settlements ever by the lawyers who represented Merck shareholders, blogger Ed Silverman writes. The trial was slated to begin March 4, less than three weeks from now, Silverman adds.